Gordon Ruthel

Dr. Gordon Ruthel


Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2004 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
PDF file
GRGordon Ruthel
Gordon Ruthel
WRWilson J. Ribot
Wilson J. Ribot
SBSina Bavari
Sina Bavari
THTimothy A. Hoover
Timothy A. Hoover
Macrophages attempt to battle infection with Bacillus anthracis spores by phagocytosis of the spores. However, it is believed that B. anthracis spore

1 April 2007 in SLAS Discovery
Verified
Journal Article
Open access
PDF file
ASAndrea M. Stahl
Andrea M. Stahl
GRGordon Ruthel
Gordon Ruthel
ETEdna Torres-Melendez
Edna Torres-Melendez
TKTara A. Kenny
Tara A. Kenny
RPRekha Panchal
Rekha Panchal
SBSina Bavari
Sina Bavari
Botulinum toxin is an exceedingly potent inhibitor of neurotransmission across the neuromuscular junction, causing flaccid paralysis and death. The potential for misuse of this deadly poison as a bioweapon has added a greater urgency to the search for effective therapeutics. The development of sensitive and efficient cell-based assays for the evaluation of toxin antagonists is crucial to the rapid and successful identification of therapeutic compounds. The authors evaluated the sensitivity of primary cultures from 4 distinct regions of the embryonic chick nervous system to botulinum neurotoxin A (BoNT/A) cleavage of synaptosomal-associated protein of 25 kD (SNAP-25). Although differences in sensitivity were apparent, SNAP-25 cleavage was detectable in neuronal cells from each of the 4 regions within 3 h at BoNT/A concentrations of 1 nM or lower. Co-incubation of chick neurons with BoNT/A and toxin-neutralizing antibodies inhibited SNAP-25 cleavage, demonstrating the utility of these cultures for the assay of BoNT/A antagonists. (Journal of Biomolecular Screening 2007:370-377)

15 March 2011 in Toxins
Verified
Journal Article
Open access
PDF file
GRGordon Ruthel
Gordon Ruthel
JBJames Burnett
James Burnett
JNJonathan E. Nuss
Jonathan E. Nuss
LWLaura M. Wanner
Laura M. Wanner
LTLyal E. Tressler
Lyal E. Tressler
SBSina Bavari
Sina Bavari
Botulinum neurotoxins (BoNTs) comprise seven distinct serotypes that inhibit the release of neurotransmitter across neuromuscular junctions, resulting in potentially fatal flaccid paralysis. BoNT serotype A (BoNT/A), which targets synaptosomal-associated protein of 25kDa (SNAP-25), is particularly long-lived within neurons and requires a longer time for recovery of neuromuscular function. There are currently no treatments available to counteract BoNT/A after it has entered the neuronal cytosol. In this study, we examined the ability of small molecule non-peptidic inhibitors (SMNPIs) to prevent SNAP-25 cleavage post-intoxication of neurons. The progressive cleavage of SNAP-25 observed over 5 h following 1 h BoNT/A intoxication was prevented by addition of SMNPIs. In contrast, anti-BoNT/A neutralizing antibodies that strongly inhibited SNAP-25 cleavage when added during intoxication were completely ineffective when added post-intoxication. Although Bafilomycin A1, which blocks entry of BoNT/A into the cytosol by preventing endosomal acidification, inhibited SNAP-25 cleavage post-intoxication, the degree of inhibition was significantly reduced versus addition both during and after intoxication. Post-intoxication application of SMNPIs, on the other hand, was nearly as effective as application both during and after intoxication. Taken together, the results indicate that competitive SMNPIs of BoNT/A light chain can be effective within neurons post-intoxication.